Replacing abstract ROI multipliers with two fully-costed flagship sprints. Both are anchored on the Apollo Hospitals biobank, executed via the LabOS agent mesh, and packaged through ClinicalBridge. Together they cover the two highest-value moments in a drug's lifecycle — pre-approval (companion diagnostics) and post-approval (pharmacovigilance).
A pharma partner has a Phase 2 oncology drug — say, a targeted therapy in NSCLC or HER2-low breast cancer. To enter Phase 3 with a stratified label, they need a regulator-grade companion diagnostic (CDx) that predicts responders. Traditional path: outsource to Roche Dx or Thermo Fisher — 4–6 years, $30–50M, parallel to clinical development, and almost always FDA-optimized with CDSCO as an afterthought.
| Phase | Months | LabOS execution | Cost |
|---|---|---|---|
| Biomarker discovery | 0–3 | OmicsOS Hypothesis Agent over Apollo NSCLC cohort (scRNA + WGS + IHC) + literature. Ranked candidate biomarkers with uncertainty. | $0.4M |
| Analytical validation | 3–9 | Design Agent emits typed DAGs; Execution Broker routes to Syngene (assay dev), MedGenome (NGS validation). Precision, accuracy, LoD/LoQ per CLSI EP05/EP17. | $1.6M |
| Clinical validation | 9–15 | Retrospective Apollo cohort (consented, IRB-approved) + prospective sub-study. QC Agent enforces sample-quality gates. Provenance-signed graph for every datapoint. | $2.5M |
| Regulatory submission | 15–18 | ClinicalBridge packages CDSCO IVD dossier + FDA pre-submission Q-Sub. Cross-agency bridging strategy. | $0.5M |
| Total | 18 months | vs. 4–6 years traditional | $5.0M vs. $30–50M |
A pharma has an approved drug — say, a DOAC (apixaban) or a CV/diabetes combination — sold at scale in India. They need Phase 4 real-world safety surveillance with pharmacogenomic signal detection. India-specific PGx variants (CYP2C9, VKORC1, CYP2C19) make Western label data structurally insufficient. Traditional path: contract a Phase 4 CRO study with manual ADR reporting + claims data — $10–30M, 3–5 years, weak India-specific signal.
| Component | LabOS execution | Annual cost |
|---|---|---|
| Real-world evidence feed | Continuous DPDP-compliant pipeline from Apollo EHR (de-identified, federated). Patient-on-drug cohort sized at 5K–50K depending on indication. | $0.6M |
| Multiomics sub-cohort | ADR experiencers (~2–5% of treated) characterized via WGS + targeted PGx panel + metabolomics. Agentic anomaly detection over the Atlas baseline. | $1.2M |
| Signal detection | QC + Learning Agents continuously refine signal-to-noise. Quarterly signal reports with PGx + ethnicity stratification. Auto-generated CIOMS-format ADR narratives. | $0.4M |
| Regulatory packaging | ClinicalBridge quarterly PSUR/PBRER inputs for CDSCO + label-update support packages for FDA/EMA when actionable signal emerges. | $0.3M |
| Total recurring | 12–18 month contracts, renew annually | $2.5M/yr vs. $10–30M one-off |
CDx = pre-approval, high-margin one-shot revenue with long-tail royalties. PV = post-approval, recurring revenue across a pharma's entire portfolio. Together they make us relevant before and after every drug launch.
Apollo biobank + LabOS agent mesh + ClinicalBridge — one platform investment, two distinct revenue streams. Marginal cost of adding the second program to an existing customer approaches zero.
CDx programs deposit deep multiomics + clinical-response data. PV programs deposit longitudinal phenotype + ADR data. The Atlas becomes uniquely complete on both response and safety dimensions — a structural lead that widens with every program.
More CDx + PV programs → richer Atlas → better India-tuned model → faster discovery → more customers → more programs. The Atlas becomes a $100M+ standalone asset by Year 5; the model becomes the licensable AI substrate of Indian biotech.